EVERLAST-A: A Phase 2a Study Design of ORKA-001, a Novel Half-Life Extended IL-23p19 Monoclonal Antibody for Plaque Psoriasis. J of Skin. 2025;9(6):s633. doi:10.25251/jg65bt44